US Supreme Court mum on Teva vs Sandoz case


No word on whether the Supreme Court will hear Teva Pharma's (TEVA -1.3%) patent case regarding the generic encroachment on its multiple sclerosis drug.

Predictably, Teva is keen to have its case reviewed in light of the US Court of Appeals verdict in July invaliding several of Copaxone's patents.

The case is, again, missing from the list of actionable cases published by the court today.

If it declines to pick up the matter generics could debut as early as May.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs